NGEN Overview

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Wall Street analysts forecast NGEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGEN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NervGen Pharma Corp revenue for the last quarter amounts to -7.53M USD, increased 24.79

NervGen Pharma Corp. EPS for the last quarter amounts to -8199650.00 USD, increased 99.08

NervGen Pharma Corp (NGEN) has 0 emplpoyees as of May 22 2026.

Today NGEN has the market capitalization of 297.83M USD.